Health-related quality of life (HRQoL) evaluation in the REGOMA trial: A randomized, phase II clinical trial analyzing regorafenib activity in relapsed glioblastoma patients

MLA

Roberta Rudà, et al. “Health-Related Quality of Life (HRQoL) Evaluation in the REGOMA Trial: A Randomized, Phase II Clinical Trial Analyzing Regorafenib Activity in Relapsed Glioblastoma Patients.” Journal of Clinical Oncology, vol. 37, May 2019, p. 2045. EBSCOhost, https://doi.org/10.1200/jco.2019.37.15_suppl.2045.

APA

Roberta Rudà, Mario Caccese, Toni Ibrahim, Francesco Pasqualetti, Ivan Lolli, Giuseppe Lombardi, Vittorina Zagonel, Bruno Daniele, Andrea Pace, P. Del Bianco, G.L. De Salvo, Riccardo Soffietti, Alba A. Brandes, S. Rizzato, Marica Eoli, Marta Padovan, & E. Bergo. (2019). Health-related quality of life (HRQoL) evaluation in the REGOMA trial: A randomized, phase II clinical trial analyzing regorafenib activity in relapsed glioblastoma patients. Journal of Clinical Oncology, 37, 2045. https://doi.org/10.1200/jco.2019.37.15_suppl.2045

Chicago

Roberta Rudà, Mario Caccese, Toni Ibrahim, Francesco Pasqualetti, Ivan Lolli, Giuseppe Lombardi, Vittorina Zagonel, et al. 2019. “Health-Related Quality of Life (HRQoL) Evaluation in the REGOMA Trial: A Randomized, Phase II Clinical Trial Analyzing Regorafenib Activity in Relapsed Glioblastoma Patients.” Journal of Clinical Oncology 37 (May): 2045. doi:10.1200/jco.2019.37.15_suppl.2045.